DUSP5

Dual specificity protein phosphatase 5 · Q16690 · DUSP5 on Sugi Atlas →

1,364 patent compounds predicted against DUSP5, 850 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18274853	1.00	4/20
Tiron (SCHEMBL22220)	0.65	4/20
SCHEMBL5310574	0.65	4/20
Chromotropate (SCHEMBL564557)	0.64	4/20
Water (SCHEMBL3205313)	0.62	4/20
Water (SCHEMBL5097417)	0.62	4/20
Ammonia Solution, Strong (SCHEMBL9751555)	0.62	4/20
SCHEMBL10722008	0.62	4/20
SCHEMBL3501680	0.62	4/20
SCHEMBL31393	0.59	4/20
Potassium Ion (SCHEMBL3222667)	0.59	4/20
SCHEMBL8717950	0.59	4/20
SCHEMBL9328871	0.59	4/20
SCHEMBL7590815	0.59	4/20
Water (SCHEMBL9466386)	0.58	4/20
Pyrophosphoric Acid (SCHEMBL10609403)	0.57	4/20
Catechol (SCHEMBL3663249)	0.56	4/20
SCHEMBL6639167	0.56	4/20
SCHEMBL1005172	0.55	4/20
SCHEMBL1650498	0.55	4/20

Clinical trials — most relevant to DUSP5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans	PHASE4	COMPLETED
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia	PHASE3	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475	PHASE1/PHASE2	UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety Study of Infusion of SGT-53 to Treat Solid Tumors	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Genetic Identification (ID) of Segmental Dysplastic Nevi	nan	WITHDRAWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Molecular Mechanisms Underlying Prostate Cancer Disparities	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DUSP5 binder may also engage these)

Protein	Name	Similarity
O54838	—	1.000	O54838 →
Q9PW71	—	0.993	Q9PW71 →
P28563	—	0.989	P28563 →
DUSP4	Dual specificity protein phosphatase 4	0.988	landscape →
Q64623	—	0.988	Q64623 →
Q16829	—	0.987	Q16829 →
Q62767	—	0.987	Q62767 →
Q63340	—	0.986	Q63340 →
Q91Z46	—	0.985	Q91Z46 →
DUSP1	Dual specificity protein phosphatase 1	0.982	landscape →
Q8BFV3	—	0.981	Q8BFV3 →
Q05922	—	0.979	Q05922 →
Q91790	—	0.976	Q91790 →
Q90W58	—	0.975	Q90W58 →
DUSP2	Dual specificity protein phosphatase 2	0.973	landscape →
Q99956	—	0.972	Q99956 →
Q9DBB1	—	0.972	Q9DBB1 →
Q5FVI9	—	0.972	Q5FVI9 →
DUSP6	Dual specificity protein phosphatase 6	0.971	landscape →
Q8BK84	—	0.971	Q8BK84 →
PTPN18	Tyrosine-protein phosphatase non-receptor type 18	0.971	landscape →
Q2KJ36	—	0.971	Q2KJ36 →
P0C595	—	0.970	P0C595 →
Q9JIM4	—	0.970	Q9JIM4 →
Q64346	—	0.970	Q64346 →
DUSP26	Dual specificity protein phosphatase 26	0.970	landscape →
Q9D0T2	—	0.968	Q9D0T2 →
GRB7	Growth factor receptor-bound protein 7	0.968	landscape →
Q5R6H6	—	0.968	Q5R6H6 →
P47823	—	0.967	P47823 →